[ Checkmate Pharmaceuticals raises $27M in Series B ]
Checkmate Pharmaceuticals has raised $27 million in Series B funding.
Founded in 2015, Checkmate Pharmaceuticals is developing a new approach for cancer immunotherapy that activates the immune system to recognize and kill tumor cells in the body.
Proceeds from the financing will be used to further advance clinical development of CMP-001, a first-in-class CpG-A oligonucleotide that activates the innate immune system via Toll-like receptor 9 (TLR9), and which is currently being studied in a Phase 1b trial in combination with pembrolizumab in primary refractory melanoma patients who have either progressed on or failed to respond to anti-PD-1 therapy.
|Founder / CEO||Arthur Krieg|
|Investors||F-Prime Capital Partners|
|Previous Investors||Sofinnova Ventures|